A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 21, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Healthy Volunteers

Interventions

DRUG

RBD4059

Subcutaneously Administered RBD4059 in Healthy Subjects.

DRUG

Placebo

Subcutaneously Administered Placebo in Healthys Subject.

Trial Locations (1)

Q-Pharm Pty Limited, Brisbane

All Listed Sponsors

lead

Suzhou Ribo Life Science Co. Ltd.

INDUSTRY